Cargando…
First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of cases. Paclitaxel has a broad spectrum of activity against various malignancies, including NSCLC. Paclitaxe...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875520/ https://www.ncbi.nlm.nih.gov/pubmed/24399877 http://dx.doi.org/10.2147/IJN.S41770 |